Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GENTLE-Z trial of initial zolbetuximab dose adjustment plus chemotherapy in CLDN18.2-positive HER2-negative advanced gastric or related adenocarcinomas
jRCTs031240347Phase 2Recruiting
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zolbetuximab in gastric cancer (GC), gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (2 arms). Primary endpoint: Vomiting-free rate in the first cycle. Started Sep 2024; status: recruiting.
02
Drugs
zolbetuximab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on jRCTs031240347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240347.